Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.67 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | GALR2 | O43603 | 3/20 | 0.35 |
| ▸ | GALR1 | P47211 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036338 | 0.88 | ROCK2 (0.63) | ROCK2KCNH2CYP3A4ROCK1 | |
| SCHEMBL10036358 | 0.88 | ROCK2 (0.63) | ROCK2KCNH2CYP3A4ROCK1 | |
| SCHEMBL10036340 | 0.88 | ROCK2 (0.63) | ROCK2KCNH2CYP3A4ROCK1 | |
| SCHEMBL10036342 | 0.88 | ROCK2 (0.63) | ROCK2KCNH2CYP3A4ROCK1 | |
| SCHEMBL6650241 | 0.86 | ROCK2 (0.57) | ROCK2KCNH2HRH4ROCK1GALR2 | |
| SCHEMBL10036351 | 0.83 | ROCK2 (0.79) | ROCK2NUDT1CYP3A4ROCK1 | |
| SCHEMBL10036350 | 0.82 | ROCK2 (0.79) | ROCK2CYP3A4ROCK1 | |
| SCHEMBL6387624 | 0.82 | ROCK2 (0.74) | ROCK2CYP3A4HRH4ROCK1 | |
| SCHEMBL5254355 | 0.81 | ROCK2 (1.00) | ROCK2CYP3A4ROCK1 | |
| SCHEMBL6396934 | 0.81 | ROCK2 (1.00) | ROCK2CYP3A4HRH4ROCK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | claimed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | claimed |
| US-6924290-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-02 | — | — | US | claimed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | ROCK2 3/4885NUDT1 2034/4885KCNH2 3207/4885 |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | CIT, ROCK1, RHOT2 | ROCK2 5/4885NUDT1 1877/4885KCNH2 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.